Treatment Efficacy for Antenatal Substance Use: A Meta-Analysis by Koller, Julie Present
	  	  
 
 
 
Treatment Efficacy for Antenatal Substance Use: 
A Meta-Analysis 
 
A Thesis 
Submitted to the Faculty 
of 
Drexel University 
by 
Julie Present Koller 
in partial fulfillment of the 
requirements for the degree 
of 
Master of Science in Clinical Psychology 
September 2013 
 
 
	  
 
.  
.  
.  
.  
.  
.  
.  
.  
.  
.  
.  
.  
.  
.  
.  
. © Copyright 2015 
.  Julie Present Koller. All Rights Reserved. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TREATMENT	  EFFICACY	  FOR	  ANTENATAL	  SUBSTANCE	  USE	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   ii	  
 
Table of Contents 
LIST OF TABLES ......................................................................................................................... iv 
ABSTRACT .....................................................................................................................................v 
1.  INTRODUCTION ......................................................................................................................1 
2.  LITERATURE REVIEW ...........................................................................................................2 
2.1 Prevalence of Prenatal Substance Use .......................................................................................2 
2.2 Teratogenic Effects of Prenatal Substance Use .........................................................................3 
2.3 Political and Legal Responses to Prenatal Drug Exposure ........................................................5 
2.4 Treatment Efficacy Research .....................................................................................................6 
2.5 Study Objectives ........................................................................................................................9 
3.  METHODS .................................................................................................................................9 
3.1 Eligibility Criteria ......................................................................................................................9 
3.2 Literature Search ......................................................................................................................10 
3.3 Data Extraction and Coding Procedures ..................................................................................10 
3.4 Statistical Analyses ..................................................................................................................11  
3.4.1 Primary Meta-Analyses ........................................................................................................11 
3.4.2 Secondary Analyses ..............................................................................................................12 
3.4.3 Calculating Effect Size .........................................................................................................12  
3.4.4 Corrections for Varying Sample Size ...................................................................................13  
3.4.5 Using Proportion or Percentage Statistics .............................................................................13  
3.4.6 Examining Heterogeneous Outcome Variables ....................................................................14 
3.4.7 Accounting for Time-Related Differences ............................................................................14
TREATMENT	  EFFICACY	  FOR	  ANTENATAL	  SUBSTANCE	  USE	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  iii	  
 
3.4.8 Examining More Than One Comparison Group ...................................................................14 
4. RESULTS  .................................................................................................................................15 
4.1 Primary Analyses .....................................................................................................................17 
4.2 Secondary Analyses .................................................................................................................19 
5. DISCUSSION ............................................................................................................................21 
LIST OF REFERENCES ...............................................................................................................27 
APPENDIX A: CODEBOOK .......................................................................................................40 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TREATMENT	  EFFICACY	  FOR	  ANTENATAL	  SUBSTANCE	  USE	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  iv	  
 
  
                                             LIST OF TABLES 
 
1. Characteristics of Outcome Studies of Drug Treatment Programs ............................................32 
2. Results from Primary Meta-Analyses ........................................................................................33 
3. Results from Moderator Analyses .............................................................................................34 
4. Pearson Correlations between Treatment Effects and Sample Characteristics .........................35 
5. Individual Study Intervention Groups, Outcome Measures, Effect Sizes, and Weights ...........36 
 
 
 
 
 
 
 
 
 
 
 
TREATMENT	  EFFICACY	  FOR	  ANTENATAL	  SUBSTANCE	  USE	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  v	  
 
Abstract 
Treatment Efficacy for Antenatal Substance Use: A Meta-Analysis 
Julie Present Koller 
 
 
 
 
This study was a meta-analysis of treatment outcome studies that have examined substance use 
treatment for pregnant women. To date, there have been no systematic reviews of this literature. 
Two independent coders collected the available studies and independently coded multiple 
variables, including statistical, methodological, client, and program factors. Quantitative 
outcomes were aggregated a) to determine whether substance use treatment programs for 
pregnant women were effective, and b) to examine additional variables, such as the type of 
intervention or treatment setting, that may have moderated the overall treatment effect. Twenty-
six studies met inclusion criteria. The overall treatment effect when aggregating across outcome 
variables was in the small to moderate range; the standard difference of means (SDM) was .3 
(p<.001). Treatment seemed to have the greatest impact (SDM=.7, p<.0001) on maternal 
outcome variables, such as employment status, comorbid mental health disorders, parenting 
skills, prenatal visit compliance, and medical and health status. When assessing the overall 
treatment effect as determined by treatment/drug use outcomes, the SDM was .3 (p<.0001). For 
birth outcomes, the overall SDM was .2 (p<.001). Both the type of intervention treatment and the 
treatment setting significantly moderated the overall treatment effect. Substance use programs 
targeting pregnant women with substance use disorders appear to be beneficial, especially when 
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a behavioral-contingency component or methadone maintenance component is added to the 
treatment protocol.  
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1. Introduction 
Maternal prenatal substance use is a pervasive and costly problem in the United States. 
This problem is especially impacting due to the large medical costs associated with pregnancy 
complications, birth complications, health problems of the newborns, and the postnatal 
environment; children born to mothers with addictions are at a higher risk for experiencing 
poverty, abuse, and neglect, and are therefore potentially in need of the intervention of juvenile 
courts and child protective services. It was estimated that costs to states for the first year 
following births affected by maternal prenatal substance abuse may be as high as $50,000 for 
each birth above the cost of normal births (Fein & Reynolds, 1990), as hospital stays are longer 
and medical costs are generally higher due to both maternal and neonatal health complications 
(Joyce, Racine, McCalla, & Wehbeh, 1995). It is estimated that over 75% of infants exposed to 
drugs have major medical problems, versus 27% of unexposed infants (Finnegan, 2000); the cost 
of treating drug-exposed infants was estimated to be about twice the cost of unexposed infants 
due to additional medical problems (Fabris, Prandi, Perathoner, & Soldi, 1998).  
Substance use treatment for pregnant women is essential for the short-term and hopefully 
long-term amelioration of this problem. Unfortunately, there are barriers preventing pregnant 
women from entering and then committing to treatment. Many women have difficulties 
obtaining the financial means, transportation, and childcare that would allow them to attend a 
treatment program. Additionally, many women fear that their child will be taken away from them 
or that they will be criminally prosecuted if they acknowledge using illicit substances. Because 
treatment attrition is especially problematic for these clients, it is critical that drug treatment 
programs address this problem and other unique needs of pregnant women. It is integral that 
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states have accessible, empirically supported, specialized substance use treatment programs for 
these women. However, there is a dearth of research examining the efficacy and effectiveness of 
the available drug treatment programs for this special population. Research evaluating the 
efficacy of specific substance use treatments for pregnant women is mixed and, to date, there 
have been no quantitative reviews of the available literature.   
This study addressed the question of drug treatment efficacy for pregnant women using 
meta-analysis techniques. Quantitative outcomes were aggregated across a large set of studies to 
examine methodological, client, and program factors that may influence the magnitude of 
treatment effects using regression analysis. This meta-analysis had several goals. The primary 
purpose of the analysis was to determine whether substance use treatment programs for pregnant 
women are effective. A secondary objective was to explore additional variables that one may 
reasonably expect from previous research to have an impact on treatment effectiveness, which 
would help provide direction for future research.  
2. Literature Review  
2.1 Prevalence of Prenatal Substance Use  
The most current estimate of prevalence of substance use among pregnant women comes 
from the National Survey on Drug Use and Health (NSDUH; Substance Abuse and Mental 
Health Services Administration, 2011), a comprehensive survey based on interviews of 67,500 
individuals in the United States in 2010 aged 12 years and older.  Results from this survey may 
be an underestimate because survey data came from self-report. According to this survey, among 
pregnant women aged 15 to 44, 4.4% reported using illicit drugs, 10.8% reported current alcohol 
use, 3.7% reported binge drinking, 1.0% reported heavy drinking, and 16.3% reported cigarette 
use based on data averaged across 2009 and 2010. Additionally, 10.1% of pregnant women aged 
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15 to 44 reported binge drinking during the first trimester of pregnancy based on the 2009 and 
2010 averaged data. Furthermore, among pregnant women aged 15 to 17, 16.2% reported current 
illicit drug use from combined 2009-2010 data. Coupling the above NSDUH survey results with 
birth data in the United States from 2009 (Martin et al., 2011), the approximate numbers of births 
in 2009 that were complicated by maternal use of illicit drugs, alcohol, and tobacco were 
181,402, 445,260, and 672,012, respectively. Maternal prenatal substance use is a widespread 
and costly national problem affecting a large number of mothers and their children.  
2.2 Teratogenic Effects of Prenatal Substance Use  
 In addition to the pervasiveness of prenatal substance use and subsequent financial 
burden to the state, there are potential teratogenic effects of prenatal exposure to drugs that may 
negatively impact the development of an infant, resulting in both short-term and long-term 
consequences. Prenatal exposure to cocaine, marijuana, and other illicit drugs has been 
associated with miscarriages, low birth weight, developmental deficits, problems with executive 
functioning, long-term behavioral problems, and nervous system damage (National Institute on 
Drug Abuse (NIDA), 2011).  Exposure to cocaine specifically has been associated with lower 
infant birth weights, congenital abnormalities, higher proportions of preterm deliveries, placenta 
abruption, antenatal death, and cognitive deficits (Handler, Kistin, Davis, & Ferrea, 1991; Lester, 
Andreozzi, & Appiah, 2004). Marijuana exposure has been specifically linked to problems with 
executive functioning; methamphetamine exposure has been correlated with fetal growth 
restriction, decreased arousal, and motor deficits in the infant; and heroin exposure has been 
associated with low birth weights (NIDA).  
Like illicit drugs, tobacco and alcohol have also been associated with negative fetal 
outcomes. Tobacco use during pregnancy has been associated with an increased risk for 
TREATMENT	  EFFICACY	  FOR	  ANTENATAL	  SUBSTANCE	  USE	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   4	  
stillbirths, infant mortality, Sudden Infant Death Syndrome, preterm births, respiratory problems, 
slowed fetal growth, low birth weights, cognitive deficits, and behavioral problems (NIDA, 
2011). Law, Stroud, LaGasse, and Niaura (2003) found a dose-response relationship between 
cotinine, a major metabolite of nicotine, in the mother’s saliva at delivery and the neuro-behavior 
of her newborn child, which suggests potential withdrawal effects in the newborn from prenatal 
cigarette smoking. Additionally, prenatal exposure to alcohol has been associated with multiple 
complications during pregnancy and after birth, including an increased risk of spontaneous 
abortion, preterm births, fetal alcohol spectrum disorders, mental retardation, developmental 
delays, cognitive deficits, and increased rates of Attention-Deficit/Hyperactivity Disorder 
(Bhuvaneswar, Chang, Epstein, & Stern, 2007). Although approximately 32% of pregnant 
women who report using illicit drugs also report using alcohol and cigarettes (Wenzel, Kosofsky, 
Harvey, & Iguchi, 2001), there is a lack of research examining the effects of polydrug use on the 
fetus of pregnant women. Because a substantial portion of prenatal drug use is polydrug use, it is 
critical that more research is undertaken to examine the effects of multiple drugs on short-term 
and long-term fetal outcome.  
It is important to emphasize that the associations between prenatal drug exposure and 
fetal outcome are not based upon causative research; many other variables interact with the 
teratogenic effects of these drugs to influence immediate fetal and more long-term 
developmental outcomes, including the amount and timing of prenatal drug exposure, risk factors 
in the environment, as well as protective and biological resiliency factors (Lester et al., 2004). 
More research is needed to examine the long-term effects of prenatal drug exposure, the effects 
of polydrug use on the fetus, and the interaction of environmental factors with long term 
developmental outcomes of children exposed to drugs in utero. Although some children who 
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have been exposed to drugs in utero have more positive outcomes than others, research supports 
that in utero drug exposure is a risk factor for developing complications during pregnancy, 
congenital and developmental abnormalities, and later cognitive and behavioral deficits.   
2.3 Political and Legal Responses to Prenatal Drug Exposure   
Over the last few decades, state legislatures have become increasingly interested in 
addressing the problem of substance use during pregnancy; research demonstrating the financial 
costs to society, the potentially detrimental effects to the fetus, and the media attention from the 
“crack baby” epidemic of the 1980s prompted the states to act to mitigate this problem (Lester et 
al., 2004). Although there are no state statutes specifically criminalizing drug use during 
pregnancy (Bhuvaneswar et al., 2007), states have passed statutes pertaining to antenatal 
substance use. More specifically, these statutes deal with the removal of children from the home, 
the termination of parental rights, the classification of antenatal substance use as child abuse, the 
identifying and reporting of drug-exposed infants, and the mandating of treatment for the 
addicted mother. 	  For example, 16 states have enacted laws that permit the removal of a child 
from a home based upon various factors, including a positive toxicology screen at birth. 
Additionally, over 25% of states have passed laws the define a pregnant woman’s drug use as 
child abuse or neglect, thereby rendering the reporting of this abuse as mandatory to appropriate 
authorities (Lester et al.).  
Antenatal substance use has been legally and politically conceptualized using two 
models: the punishment model and the treatment model. The punishment model is a more 
conservative approach that views prenatal substance use as a criminal act warranting sanctions 
within both the child protection system and the criminal justice system. The other more liberal 
approach, the treatment model, considers prenatal substance use as an illness, and advocates 
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treatment and prevention as a way to reduce the frequency and effects of this problem. Although 
legislatures differ in how they view the nature of addiction, the status of the fetus, the autonomy 
of pregnant women, and the need for punitive measures, they agree that treatment is a central 
component to state policy regarding substance use during pregnancy. Treatment may be 
mandated or encouraged; multiple states use drug courts that encourage treatment and 
rehabilitation services as opposed to jail time. Approximately 25% of states have laws that 
mandate the state establishment of treatment programs for pregnant substance users (Lester et al., 
2004). The overarching state goal is to identify, entice, or mandate pregnant women who use 
drugs to enter an available treatment program and achieve abstinence.   
The underlying assumption to state policy then is that treatment is effective. However, 
treatment efficacy research for this population is limited and mixed. There have been no 
systematic studies to date that have quantitatively examined the literature to answer the 
following question: do current models of treatment work for pregnant women with substance use 
disorders?  
2.4 Treatment Efficacy Research  
Pregnant women who use drugs have special needs with regard to addictions treatment 
programs. These women often present with psychiatric comorbidities, financial problems, 
criminogenic needs, childcare needs, vocational skill deficits, and parenting deficiencies 
(Bhuvaneswar et al., 2007; Daley et al., 2000; Kelly, Zatzick, & Anders, 2001). In addition, 
pregnant substance users frequently present with comorbid medical complications; one study 
showed that 27% of pregnant women entering a day treatment program in New York City tested 
positive for HIV (Egelko, Galanter, Edwards, & Marinelli, 1996). Comprehensive treatment 
programs are necessary to address these special factors that may be contributing to and 
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maintaining the substance use disorder. Unfortunately, treatment programs often rely on male-
based recovery models and ignore the unique context and needs of pregnant substance users 
(Lester et al., 2004). The development of treatment programs specific to this population is 
necessary to improve treatment retention, adherence, and efficacy.  
Beginning in the 1980s, with the increase of research linking in utero cocaine exposure to 
negative fetal outcomes and the resulting media attention of crack- and cocaine-exposed infants, 
government agencies such as NIDA and the Center for Substance Abuse Treatment (CSAT) 
began funding the development of treatment programs for pregnant women with substance use 
disorders. In the late 1980s, NIDA funded 20 research demonstration projects that focused on the 
treatment of this population (Lester et al., 2004).  Since that time, there has been an increase in 
the number of treatment options available to pregnant women who use drugs, including inpatient, 
outpatient, residential, short-term, long-term, methadone-maintenance, detoxification only, 
women-only, and other variations and combinations of the above treatment programs. Although 
the short-term clinical gains from these treatment programs seem promising, and the longer-term 
clinical gains are often unexamined, more research is needed to verify these benefits.  
There are both naturalistic problems for providing substance use treatment to this 
population, as well as problems with researching the efficacy and effectiveness of these 
treatment programs. Numerous barriers to treatment exist for pregnant women who use drugs. 
These include a fear of criminal prosecution, a fear of losing their children, difficulties in 
accessing transportation and funds to attend treatment programs, difficulties finding childcare to 
allow for treatment attendance, and difficulty accessing treatment more generally. Furthermore, 
many treatment programs limit the attendance of pregnant substance users for fear of harming 
the fetus with medications used for detoxification, as well as fear of liability for negative birth 
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and fetal outcomes. Research has shown that retention rates and treatment outcomes are 
improved with longer treatment stays (Fiocchi & Kingree, 2001), more specialized psychosocial 
support services, and when treatment is shared with other pregnant women with substance use 
disorders (Grella, Joshi, & Hser, 2001). Few programs have the resources to provide 
comprehensive services to address the unique needs of this population with additional 
psychosocial supports (Bhuvaneswar et al., 2007).  
Given the above barriers to treatment, it is not surprising that retention rates are often 
poor; retention rates for pregnant substance users in specialized treatment programs are often 
worse than non-pregnant individuals in more generalized substance use treatment programs 
(Fiocchi & Kingree, 2001). Success of treatment programs is often related to retention rates 
(Howell, Heiser, & Harrington, 1999). Improving retention rates is important to yield better 
treatment outcomes, as well as more meaningful studies of treatment efficacy; high attrition rates 
are one of many problems encountered when examining treatment efficacy for this population. In 
addition, research in this area often lacks control or comparison groups, long-term follow-up 
studies, large sample sizes, and consistent operational definitions of substance use. Outcome 
measures vary, and substance use treatment for pregnant women is often expensive to 
implement. Given these impediments to examining the treatment options for this costly and 
impacting problem, a lack of treatment outcome research exists for this specific population of 
women, especially when compared to other populations of substance users. A current systematic 
analysis of these treatment programs is therefore warranted to improve clinical care and 
decision-making, help guide state policy, inform future research, and further reduce the 
economic burden of Antenatal substance use.  
 
TREATMENT	  EFFICACY	  FOR	  ANTENATAL	  SUBSTANCE	  USE	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   9	  
2.5 Study Objectives 
 The primary objective is to determine whether treatment programs for pregnant substance 
users are effective. This meta-analysis will quantitatively examine the magnitude of the 
treatment effect of interventions for pregnant substance users. A secondary objective will be to 
explore additional variables, like type of treatment intervention and treatment setting, that may 
impact treatment efficacy.  
      3. Methods 
3.1 Eligibility Criteria 
 Eligible studies were outcome evaluations of drug use treatment programs for pregnant 
women published or issued from 1965 through 2012, using quasi-experimental and experimental 
designs, including either single-group pre-posttest designs, treatment-comparison group designs, 
or treatment-control group designs; inclusion was limited to studies with these designs because 
they permit the strongest statistical conclusions. The symptom of primary interest was antenatal 
substance use, which was broadly defined as the use or abuse of one or more illicit drug or 
alcohol during pregnancy. Study participants were pregnant at the time of the intervention. All 
studies must have examined an adult-aged sample (>18 years old). Studies must have been 
published in English. Unpublished studies retrieved through correspondence with contributors in 
the fields of antenatal substance use and maternal health outcome studies were also included. All 
studies must have contained quantitative data needed to calculate an effect size (e.g., means, 
standard deviations, percentages, number of participants) on at least one outcome variable. If this 
information was not reported, or only partially reported, then attempts were made to obtain these 
data by contacting the authors or calculating the appropriate statistics. Excluded studies included 
case studies (because they would not permit applicable statistic conclusions) and multiple 
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publications related to the same study (because they may overestimate that study’s treatment 
effect). The eligibility criteria guided the selection of terms used to search electronic databases, 
as well as the subsequent coding procedures.  
3.2 Literature Search  
The search, retrieval, and selection of studies were based on the eligibility criteria and 
conducted independently by two independent coders (research assistants).  Computer-based 
searches of MEDLINE, Psych INFO, Clinical Health, PsychArticles, Social Science Fulltext, 
Web of Knowledge, Health Source, PubMed, Dissertation Abstracts, conference abstracts, and 
reference lists were conducted to identify substance use treatment outcomes studies for antenatal 
substance use. Key search criteria combined the terms substance use (e.g., alcohol abuse, drug 
dependence, substance use, addiction), pregnancy (e.g., pregnancy, antenatal, birth outcomes), 
and treatment programs (e.g., treatment outcome, interventions, substance use treatment 
programs). Studies in progress were searched through a search of the National Institutes of 
Health CRISP database of funded research.  
3.3 Data Extraction and Coding Procedures 
Two independent coders identified studies that met eligibility criteria. Both coders were 
advanced undergraduate students with psychology majors at Drexel University. Both coders 
(each blind to the other’s rating) rated each study. Inter-rater reliability was assessed both during 
the coder-training period and during the formal coding of the full sample. The index of inter-rater 
reliability was the percentage of agreement between coder data on 10% of the full sample; a 
percentage of 80 or greater was considered sufficient. During the training period, three 
demonstration studies were selected to determine the percentage of agreement between the coder 
ratings. Subsequently, the percentage of agreement was calculated for 10% of the first half of the 
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studies that were coded; these studies were selected at random. Throughout the duration of the 
study, differences were resolved by discussion and new decision rules were continually added to 
the Codebook (See Appendix).  A final calculation of inter-rater reliability was conducted at the 
conclusion of the data collection process; 10% of the last half of the studies coded were selected 
at random and a percentage of agreement was calculated.   
Coders were trained during a 2-week training period during which they followed the 
Coding Standard Operating Procedures Manual to practice coding sample studies. This manual 
described each of the codebook’s variables in detail, and was updated as needed throughout the 
study. The codebook consisted of questions pertaining to the following seven categories: study 
characteristics and context, participant characteristics, methodology, treatment characteristics, 
dependent variable characteristics, study results, and effect size calculation. Database design, 
utilization, and maintenance, as well as all statistical analyses were conducted using the SPSS 
Version 20 statistical software package. The database was stored on a password-protected Drexel 
University computer. All studies were given a number in the database. All documents associated 
with the same study were grouped under the umbrella of a single study number and coded 
aggregately for that particular study.  
3.4 Statistical Analysis   
3.4.1 Primary meta-analyses. 
The primary analyses in this study involved calculating an overall treatment effect after 
aggregating across outcome measures and comparison groups. A random effect model was used 
because of the high heterogeneity expected among the collected studies; this model assumed that 
the true effect would vary from study to study. Q and I2 statistics were calculated to test for the 
amount of heterogeneity among studies. Meta-analyses were also conducted for each subgroup 
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of outcome measures, including drug/treatment outcomes, quality of life outcomes, and birth 
outcomes.  Publication bias was detected using a fail-safe N approach to determine how many 
missing studies would be needed to bring the overall effect to a specified level, or rather, to 
determine if publication bias is entirely responsible for the observed effect. Additionally, the 
Begg and Mazumdar rank correlation was used to further detect the existence and extent of 
publication bias.  
3.4.2 Secondary analyses.  
Moderators of the overall treatment effect were examined using mixed effect analyses, 
again assuming a high level of heterogeneity between studies. The type of intervention and the 
treatment setting were assessed as potential moderators in this study. Furthermore, Pearson 
correlations were conducted between each study’s treatment effect and the mean gestational age 
at entry, the length of treatment, and the percent of attrition within a study. Correlations were 
considered significant at the two-tailed alpha level of .05.  
3.4.3 Calculating effect size.  
Comprehensive Meta-Analysis (CMA) software was used to determine each study’s 
treatment effect size and the overall treatment effect for the meta-analysis; all primary and 
secondary analyses were conducted using CMA. Descriptive analyses were conducted using 
SPSS. The statistical methods that were used to calculate, combine, and analyze effects sizes 
were those of Hedges and Olkin (1985), supplemented by procedures described in Cooper and 
Hedges (1994). An effect size – the standard difference of means (SDM) between treatment and 
comparison conditions – was calculated for each study. The most common type of effect size for 
treatment evaluation and outcome studies in the social science literature is the SDM, which is 
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computed by subtracting the mean outcome score of the comparison/control group from that of 
the treatment group and dividing the difference by the pooled standard deviation:  
g= (Mt- Mc) / SDpooled 
where Mt and Mc are the means of the treatment and comparison/control groups, respectively, 
SDpooled is the pooled estimate of the standard deviation, and g is the effect size estimate. If 
means and standard deviations were not available, effect sizes were calculated from the reported 
value of the t, F, p, odds ratio, or χ2 statistics, using formulas found in standard meta- analysis 
texts (see Cooper & Hedges, 1994; Hedges & Olkin, 1985). The alpha level for the primary 
meta-analyses and secondary analyses was two-tailed at .05.  
3.4.4 Corrections for varying sample size.  
Because effect sizes calculated from means and standard deviations in studies with small 
samples provide overestimates of the population effect size, it has become standard practice, 
following Hedges and Olkin (1985), to apply a correction to all such effect sizes, regardless of 
sample size, to provide an (approximately) unbiased population effect size estimate d: 
d=[1-  (3  /(4Nt + 4Nc - 9) ] X g 
where Nt is the sample size of the treatment group, Nc is the sample size of the comparison 
group, and g is the effect size estimate. Because studies with large samples provide more precise 
and stable estimates of the population effect size than do studies with small samples, standard 
meta-analytic practice is to weigh each effect size estimate by the inverse of its variance. In this 
analysis, each study was given a weight based upon sample size.  
3.4.5 Using proportion or percentage statistics.  
Effect sizes for results reported as proportions or percentages were calculated using the 
arcsine transformation suggested by Cohen (1988): where p1 is the proportion of “success” for 
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the treatment group and p2 is the proportion of “success” for the comparison group. Unlike the 
correction factor described for means and standard deviations, there is no correction available in 
the literature to reduce small-sample bias for effect sizes calculated from proportions or 
percentages (g is assumed to equal d). 
3.4.6 Examining heterogeneous outcome variables.  
If each outcome measure were treated independently, like a separate study, then more 
weight would be assigned to studies with more outcomes, and separate outcomes would be 
assumed to contain independent correlations; outcomes may be correlated to each other in some 
way. To account for these potential statistical problems, every study was represented by one 
effect size regardless of the number of outcomes included in the mean. In this way, more weight 
was not assigned to studies with more than one outcome measure. The formula for the variance 
of this synthetic variable took into account the correlation of the outcomes.   
3.4.7 Accounting for time-related differences.  
Because many studies report outcome results for multiple measurement points (e.g., 
during treatment, end of treatment, post-treatment), there was often more than one time-related 
measure of the same dependent variable in a particular study. In such cases (to avoid creating 
dependencies among dependent variables within such studies), effect sizes were calculated at the 
first post-treatment assessment point; if all measures were taken during treatment, then effect 
sizes were calculated based upon the assessment point nearest to the end of the treatment.  
3.4.8 Examining more than one comparison group. 
To examine more than one comparison group within a study, a synthetic effect size 
(mean effect size) for each study was created; like with multiple outcome measures, the variance 
took into account the correlation among the different treatments.  
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4. Results 
Twenty-two studies met inclusion criteria. All studies were journal articles that reported 
on protocols funded by the federal government. Nineteen of the studies were specifically 
targeting pregnant women, and the remaining targeted both an antenatal and postnatal 
population. Although 22 studies were collected, three studies were subdivided into multiple 
cases. One study included results from three independent samples and comparisons, and so these 
results were recorded as three separate cases. Two other studies similarly reported two separate, 
independent treatment comparisons within their results, yet utilized the same samples for these 
separate comparisons, and so were coded as four separate cases. One of these studies examined 
subsets of the sample in two types of comparisons, and so both sets of comparison groups were 
analyzed separately in all analyses. Two other separate studies utilized the same group of 
participants yet examined two separate types of comparisons: a comparison of treatment 
components, and a comparison of participants who experienced external pressure versus those 
who did not experience external coercion to attend treatment. In total, there were 26 treatment 
effect sizes that were included in the final sample for this meta-analysis. Table 5 delineates 
individual study characteristics and effect size estimates for these 26 separate analyses. Table 2 
shows results from the primary meta-analysis conducted from these 26 cases. Another meta-
analysis was also calculated eliminating two effect sizes from these redundant samples to reduce 
overlap and potential correlations between treatment results. One effect size from a duplicate 
sample was removed which examined the effects of external pressure on treatment outcome 
because “external pressure” is not an inherent treatment component per say, and one effect size 
was removed which examined subgroups ((a 3 day versus a 7 day methadone assisted 
withdrawal)) because it was a secondary analysis and was not the primary comparison examined 
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in that particular study. These removals brought the total number of effect sizes used in a second 
meta-analysis to 24 separate statistics. See Table 2 for results from this meta-analysis as well. All 
descriptive data that were calculated reported on information from these 24 cases to avoid 
complete sample overlap. Inter-rater reliability was high at each assessment point, with over a 
95% rate of agreement between coders throughout the study. 
There were a total of 18,172 pregnant participants across studies. The average sample 
size was 757 (SD=1607.3) participants per study. Of the 18 studies that reported racial or ethnic 
characteristics, the mean percentage of white women was 41.3% (SD=20.5%), of black women 
was 47.3% (SD=24.3%), of Hispanic women was 14.4% (SD=5.8%), and of “Other” was 
19.05% (SD=24.3%). One study reported a sample as composed of 6.0% American Indian 
women. Of note, no Asian or Native Hawaiian participants were reported in any study. Overall, 
participants spent an average time of 33.5 (k=7) weeks in treatment, with the median being 16 
weeks. The mean age of the total sample was 28.0 (SD=2.03) years. The mean gestational age 
when treatment was started was 19.6 weeks (k=11, SD= 3.9). The mean attrition rate across 
studies was 26.8% (k=17, SD=22.2%), and the mean length of the treatment protocols was 28.3 
weeks (k=10, median=12.0, SD=49.5). Two studies reported the frequency of service utilization, 
and the mean frequency among participants was 74.8%. Six studies collected data on 
participant’s comorbid mood disorders and one study examined anxiety disorders; the average 
percent of the sample with a mood disorder was 46.5% (SD=21.5%), and the percent of 
participants with a comorbid anxiety disorder was 41.6%. Of the four studies that reported the 
frequency of HIV among participants, the mean frequency was 8.0% (SD=5.5%). The one study 
that examined the rate of domestic violence reported that 54.7% of the participants had 
experienced this trauma.  
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Table 1 describes the treatment characteristics of the included studies, including the 
publication date, the type of intervention condition, the research design of the protocol, the 
assignment procedure, the type of substance use examined, and the treatment setting. Most 
treatment procedures were carried out in a comprehensive care setting or addiction rehabilitation 
facility. The majority of studies examined pregnant substance users who reported abusing 
multiple drugs concurrently; 41.7% of studies examined “polydrug” abuse, and 25% examined 
concurrent, “primary opiate and cocaine” abuse. Residential treatment programs were repeatedly 
examined, as well behavioral contingency- or voucher-based- treatment protocols, which were 
often add-on treatment components to intensive outpatient or residential programs.   
4.1 Primary Analyses 
One effect size statistic – the standard difference of means (SDM) – was calculated for 
each case for the primary meta-analysis. Each study was weighted based upon sample size and 
these weights were factored into the final effect size determination. Statistics yielded from 
outcome measures within an individual study were aggregated and the mean was used in the 
effect size determination. Similarly, statistics yielded from multiple comparison groups within a 
study were aggregated and averaged in the final effect size calculation. Because of the high level 
of heterogeneity among the studies, which was further confirmed by significant Q statistics and 
high I2 values (see Table 2), random effects analyses were used throughout the primary and 
secondary effect size calculations.   
Full results for all primary analyses are reported in Table 2. For the full meta-analysis 
(K=26), the SDM was .322 (z=6.9, p<.0001), which is a low to moderate overall treatment 
effect. To correct for publication bias – namely the file drawer effect – a fail-safe N procedure 
was applied to the results, which revealed that the number of missing studies that would bring 
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the p value to greater than an alpha level of .05, with 2 tails, was 984 studies. This suggests that 
the significant results in this study are not due to an influence of missing data. Another 
publication bias control method, the Begg and Mazumdar rank correlation, was applied as well, 
as it was suggested by Kromrey and Rendina-Gobioff (2006) that although methods to detect 
publication bias often lack statistical power and sufficient type 1 error control, the Begg and 
Mazumdar rank correlation method suggests more statistical power and type 1 error control 
compared to other formal publication bias detection methods, such as the Funnel Plot 
Regression, Egger’s Regression, and the Trim and Fill method. This correlation examines the 
relationship between the standardized treatment effect and the variance of the treatment effect 
using Kendall’s Tau. Ranks are assigned for the observed standardized treatment effects and the 
variance of those treatment effects; the correlation between these ranked values (Kendall’s tau) 
leads to a statistical test designed to detect publication bias. Using this method, Kendall’s tau 
with a continuity correction was calculated for the primary meta-analysis (tau=.222, z=1.59, 
p>.05), suggesting that there is not sufficient evidence that publication bias exists in this sample 
of studies. A second meta-analysis was conducted extracting the studies with duplicate samples. 
Similar to the above analysis, a small to moderate effect size point estimate was determined; the 
SDM was .308 (k=24, z=6.5, p<.0001).  
Because outcome measures were aggregated and averaged for the primary treatment 
effect analysis, further analyses were conducted to examine if the type of outcome measure 
would yield disparate effect sizes. Outcome measures were divided into three categories: 
treatment/drug use outcomes, quality of life outcomes, and birth outcomes. The specific outcome 
measures that were aggregated for the treatment/drug outcome category were abstinence rates, 
cigarette use, cocaine metabolite measures, relapse rates, self-reported drug use, self-reported 
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cocaine use, self-reported heroin use, urine toxicity report, urine toxicity report (cocaine), urine 
toxicity report (opiate), and time in treatment/treatment completion. For this meta-analysis 
examining treatment/drug outcomes, the SDM was 0.3 (k=18, z=5.5, p<.0001), suggesting a low 
to moderate treatment effect. For the quality of life outcome category, the following outcomes 
were included in this analysis: arrest outcomes, criminal activity, depressive symptoms, PTSD 
checklist scores, employment rates, family functioning, health/medical problems, number of 
prenatal visits/compliance with prenatal visits, on welfare, parenting skills, self-esteem. For this 
meta-analysis examining maternal outcomes, a moderate to high treatment effect was found; the 
SDM was 0.7 (k=9, z=4.1, p<.0001). Finally, a separate meta-analysis was conducted with regard 
to birth outcomes. The following outcomes were included in this category: admission to ICU, 
adverse perinatal outcomes, birth weight, fetal demise, gestational age at delivery, head 
circumference, infant death, intrauterine growth retardation, need for neonatal abstinence 
syndrome (NAS) treatment, need for neonatal assisted ventilation, neonate need for morphine 
treatment, placental abruption, preterm delivery rates, preterm labor, and time spent in hospital 
after birth. The overall effect size for the birth outcome category was .2 (k=9, z=2.8, p<.0001) , 
suggesting a small treatment effect with regard to birth outcome variables.  
4.2 Secondary Analyses 
Moderator analyses were conducted to explore significant variability in effect sizes that 
could not be explained by outliers alone. Moderator analyses were conducted for two categorical 
variables: intervention type and treatment setting.  Based on Hedges and Pigott’s (2004) method 
for examining potential categorical moderating variables in meta-analyses, the between-level Q 
statistic was calculated for both moderator variables. This entailed calculating the overall Q 
statistic and subtracting the Q value produced by each individual level of the moderator variable. 
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According to Hedges and Pigott, if the between-level Q statistic is significant, the moderator 
accounts for a significant portion of the overall variability.    
For the purposes of this study, moderator analyses were conducted on effect sizes based 
on aggregate outcome measure means. Intervention type and treatment settings were examined to 
determine if either had a significant moderating effect on the overall treatment effect and 
accounted for a significant amount of variability. Mixed effect analyses were used with a random 
effects model to combine studies within subgroups because studies included in this meta-analysis 
displayed a high amount of heterogeneity. The study-to-study variance was not assumed to be 
the same for all subgroups; this value was computed within subgroups and was not pooled across 
subgroups. 
Table 3 shows results from the mixed effect, moderator analyses. Based on the between-
level Q statistics, the type of intervention treatment group was a significant moderator (Q=56.2, 
df=6, p<.001) on the overall treatment effect, as was the type of treatment setting (Q=34.6, df=4, 
p<.0001). A closer examination of the moderator analysis of intervention type revealed that 
community based treatment (k=2) and the detoxification program (k=1) did not yield standard 
effect sizes that were found to be statistically significant; in fact, the detoxification program 
yielded a negative overall treatment effect. Both the methadone maintenance  (k=1, SDM=1.3, 
p<.0001) and the methadone-assisted withdrawal (k=1, SDM=.8, p<.0001) programs yielded 
high effect sizes, the behavioral contingency or voucher-based treatment programs yielded a 
moderate effect size (SDM=.5, p<.001), and the residential programs (SDM=.2, p<.001) and the 
intensive outpatient programs (SDM=.2, p<.01) yielded relatively small treatment effects. With 
regard to treatment setting, the majority of the protocols were either carried out in an addiction 
rehab facility (k=11) or a comprehensive care setting (k=10). Interestingly, those carried out in 
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an addiction rehab facility yielded a moderate to high treatment effect size (SDM=.6, p<.001), 
whereas those carried out in a comprehensive care setting yielded a low treatment effect 
(SDM=.2, p<.001). It could be that treatment settings dedicated exclusively to substance use 
disorders may be more efficacious than those that delivery treatment services for a wider range 
of psychiatric and medical problems. Of note, the one study carried out in an outpatient setting 
yielded a large treatment effect size (SDM=.8, p<.0001), whereas the studies carried out in a 
hospital (k=1) or primary care setting (k=1) yielded very small effect size estimates.  
Finally, correlations were conducted to determine if mean gestational age, treatment 
length, or attrition rates were correlated with individual study effect sizes. The results of these 
bivariate correlations are reported in Table 4. A large positive correlation was found between 
treatment length and treatment effect sizes (r=.5, k=11); the longer the treatment length, the 
better the treatment outcome. There was a medium negative correlation between the mean 
gestational age at entry and treatment effect size (r=-.3, k=10); the earlier a woman entered 
treatment according to gestational age, the better the treatment outcome. Finally, there was a 
small negative correlation between attrition rates and treatment effects (r=-.1, k=17); the lower 
the attrition rate, the better the treatment outcome. Although these correlations reveal interesting 
and potentially important patterns in the data, none of these calculated Pearson correlations 
reached a level of statistical significance. The relatively small number of studies included in 
these correlation analyses may explain this lack of statistical significance.   
5. Discussion 
The purpose of this study was to quantitatively determine the overall treatment effect for 
current substance abuse treatment programs targeting pregnant women with substance use 
disorders. Attrition, cost, and ethical considerations have limited the number of empirical studies 
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that have been implemented that have specifically examined this high-risk population. Because 
of the relatively small number of existing studies, this meta-analysis was designed to be as 
inclusive as possible. This meta-analysis determined that substance abuse treatment programs for 
pregnant women were beneficial; the average (weighted) effect size was 0.3 after aggregating 
data across outcome measures and comparison groups. Although this is a small to moderate 
effect size, it is statistically significant, and it does suggest that pregnant women are helped from 
the examined treatment programs.  When examining outcome measure categories separately, the 
SDM for quality of life outcomes was high (SDM=.7), suggesting that these program improve 
overall maternal quality of life, including health status, comorbid mental health problems, 
parenting skills, and family functioning. Although aggregating these quality of life outcomes was 
somewhat arbitrary, as these outcomes vary in their potential correlations with each other and in 
the life domain in which they attempt to assess, these outcome measures all measure maternal 
functioning outside of the specific domain of substance use and treatment compliance. Because 
of the exploratory nature of this study, the high treatment effect yielded from the aggregation of 
these outcome measures is suggestive, at the least, that substance abuse treatment may be 
addressing – and may need to address- comorbid problems exhibited by this population of 
women. For example, comorbid depression and anxiety symptoms significantly statistically 
decreased in many of these treatment protocols; further examining the direct or indirect effects of 
these substance use programs on these symptoms would be an area for future research. Unlike 
these quality of life outcomes, the SDM for treatment and drug outcomes was at the small to 
moderate level, suggesting that substance abuse treatment reduces the frequency of drug use and 
relapse rates; certain treatment programs, such as contingency or voucher-based treatment 
protocols, specifically reduce attrition rates and increase the amount of time spent in treatment. 
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Although the separate meta-analysis conducted examining birth outcomes yielded the smallest 
SDM of the three outcome categories, the SDM was still statistically significant and suggests 
that the current substance use programs may benefit the growing fetus, at least more than no 
treatment or treatment without targeting substance abuse specifically.      
Due to the limited research in this area, this meta-analysis strived to be as inclusive as 
possible to capture as much of the treatment outcome literature to date on this specific population 
of women. With this high level of inclusivity, however, came a problematic internal validity 
within this meta-analytic design. This study quantitatively analyzed studies with a large variety 
of treatment outcome measures, research designs, and comparison groups. To correct for this 
high level of heterogeneity, a random effects model was used in these analyses, studies were 
weighted based on sample sizes, and separate meta-analyses were conducted on different types 
of outcome measures. Publication bias methods were also conducted to detect potential file 
drawer problems and Type 1 errors. With more research conducted on treatment programs for 
pregnant substance users, more homogenous studies may be collected and used in a meta-
analysis to improve upon the internal validity that suffers from aggregating across such diverse 
outcome studies.  
Despite the limitations discussed above, the aggregate treatment effect size found in this 
study suggests a benefit from the substance abuse treatment programs currently available to 
pregnant women, yet it also elucidates the need for further improvement of these programs. 
Pregnant women who are pressured into treatment, who have a voucher-based or contingency-
based component to their therapy, who seek treatment in an addiction facility, and who are in a 
long-term or residential based program seem to have the best outcomes. Additionally, a 
methadone-maintenance component included in the treatment protocol seems to improve the 
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treatment outcome as well. The higher SDM yielded from the meta-analysis of quality of life 
outcomes suggests that although abstinence and normal pregnancies and births may not be 
obtained with a compelling frequency among this population, it does suggest that complying 
with substance abuse treatment affects other, also profound, areas of a woman’s life, such as 
their employment status, their relationship with criminal activities, their compliance with 
prenatal visits, their comorbid mood and anxiety symptoms, and their functionality as a parent to 
their existing children. Substance abuse treatment programs which include parenting training, 
individual therapy, group therapy, child care, post-natal care, and skills-based groups may be 
contributing to the improvement of functioning in multiple domains of the pregnant woman’s 
life.  
While improving substance use treatment programs to better serve this vulnerable, high-
risk population should be a continual striving, the impediments of cost and access will still be 
barriers to treatment compliance and completion. It is clear that the length of the treatment 
program and the length of stay both improve treatment outcome. Surprisingly, however, the 
studies examined in this sample did not demonstrate extremely high rates of attrition; the average 
attrition rate was 26.8%, which, although substantial, is not alarming. In other words, an average 
of 73.2% of participants were considered treatment completers. External pressure to attend 
treatment, whether through legal or coercive social pressures, or internal pressure to comply with 
treatment such as the use of vouchers may further decrease the attrition rate among pregnant 
substance users. It is important to conduct more research on the type of pressure that may 
enhance attrition and treatment success rates for this population. With regard to a general 
substance user population, research suggests that external pressure- including legal and coercive 
social pressure, usually by family members- improves treatment entry, participation, and 
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retention; Wild, Roberts, and Cooper (2002), in their review of the empirical literature on 
coercive drug abuse treatment, found that with regard to treatment outcomes, the majority of 
studies comparing compulsory versus non-compulsory treatment report superior treatment entry, 
participation, and retention for the general population with substance use disorders. More 
research on the effects of external pressure on treatment outcome for pregnant women 
specifically may be directly applicable to policy-making.  
It is interesting to note that the resulting overall treatment effect size that was calculated 
in this meta-analysis is similar to results from a meta-analysis examining substance abuse 
treatment programs on the general population of substance users. Prendergast, Podus, Chang, and 
Urada (2001) conducted a meta-analysis of the effectiveness of drug abuse treatment based on 
treatment comparison studies (K=78); they found that the average, adjusted, weighted effect size 
was .3 for drug use outcomes. This small to moderate overall effect size is analogous to the 
effect size calculated in this study examining similar treatment for pregnant substance users. In 
another meta-analysis conducted by Prendergast, Podus, Finney, Greenwell, and Roll (2006), it 
was found that contingency management techniques used in treating substance use disorders had 
a moderate to high treatment effect size. Among the 47 studies with a treatment-control group 
design, they found that the mean overall effect size was moderate (d=.4), but that the use of 
contingency management to treatment opiate use yielded a moderate to high treatment effect size 
(d=.7), as well as for cocaine use (d=.7). This further suggests, as discussed above, that 
contingency management components to treatment may especially improve treatment outcomes 
for substance users in general, but also for pregnant women with substance use disorders.  
Finally, due to the small to moderate effect size obtained in this study, it should be 
recommended that pregnant substance users attend a treatment program; the effects are not null 
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but clinically salient. Overall, the programs that have been examined, to date, have been found to 
be at least mildly beneficial to this population. However, there are deficiencies in the current 
research base that should be explored and addressed; critical variables should be assessed in 
future research protocols that may impact treatment outcome and may then lead to improved 
treatment protocols. For example, only one study reported on domestic violence specifically and 
only four studies reported on the frequency of HIV among these pregnant women. Furthermore, 
only one study reported on comorbid anxiety disorders (via the PTSD symptom checklist) and 
only six studies reported on comorbid mood disorders. Pregnant women who have experience 
trauma, violence, comorbid medical complications such as HIV, or who present with depressive 
and/or anxiety symptoms should be assessed for these experiences; these other important 
treatment needs then should be incorporated into their treatment program. Another deficit in the 
current literature is the lack of attention to confounding factors that may affect birth outcomes- 
such as the examination of nutrition deficiencies, sleeping problems, the use of psychotropic 
drugs, cigarette smoking, comorbid psychiatric and medical disorders (as mentioned above), and 
other complicating factors. Future research should assess for these important domains that may 
also have detrimental effects on fetal development. Additionally, more research should be 
conducted to evaluate the specific effects of mandatory versus voluntary treatment attendance, as 
well as if more punitive components of treatment, or more benign contingencies- such as 
voucher-based contingencies or external social pressure, would directly influence treatment 
outcome. This would be important for clinicians, patients, and policy-makers alike; due to the 
potential high stakes of substance use among pregnant women, this research is both critical and 
urgent.  
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Table 1 
Characteristics of outcome studies of drug treatment programs 
(K=24) 
       K    % 
Publication date 
 1990s        7   29.2 
 2000s      10   41.7 
 2010s        7   29.2 
Type of intervention treatment 
 Behavioral contingency      7   29.2 
 Community-based      2     8.3 
 Detoxification       1     4.2 
 Intensive outpatient      4   16.7 
 Methadone-assisted withdrawal    1     4.2 
 Methadone maintenance     1     4.2 
 Residential       8   33.2 
Treatment setting 
 Addiction rehab    11   45.8 
 Comprehensive    10   41.7 
 Hospital       1     4.2 
 Outpatient       1     4.2 
 Primary care       1     4.2 
Type of sample substance use 
 Polydrug     10   41.7 
 Illicit        1     4.2 
 Cocaine       2     8.3 
 Opiates       5   20.8 
 Opiates and cocaine      6   25.0 
Type of research design 
 Single group, repeated measures    6   25.0 
 Active comparison     11   45.8 
 Passive comparison      4   16.7 
 Active and passive comparison    3   12.5 
Assignment procedure 
 Random or quasi-random   10   41.7 
 Nonrandom, no matching    14   58.3 
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Table 2 
Results from Primary Meta-Analyses  
Type of Meta-
Analysis (MA)  
K SDM 
(95%CI) 
SE V Z Q df I2 
Full MA  26 .32 
 (.23-.41) 
.046 .002 6.94*** 144.50*** 25 82.70 
MA w/o 
duplicate 
samples 
24 .31  
(.21-.40) 
.048 .002 6.45**** 135.93**** 23 83.08 
MA with 
treatment/ 
drug outcomes 
18 .32  
(.20-.43) 
.058 .003 5.48**** 90.17**** 17 81.15 
MA with 
maternal 
outcomes  
9 .73 
 (.38-1.07) 
.18 .031 4.12**** 117.93**** 8 93.22 
MA with birth 
outcomes  
9 .21  
(.07-.36) 
.006 .006 2.83**** 18.79* 8 57.42 
Notes: *p<.05. **p<.01. ***p<.001. ****p<.0001.  
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Table 3 
Results from Moderator Analyses 
Variable cluster K SDM (95%CI) SE V Z Q df 
        
Intervention 
Group 
       
Behavioral 
Contingency 
7   .49(.28-.70) .11 .012 4.50****   
Community 2   .42(-.26-1.09) .34 .12 1.22   
Detoxification 1  -.19(-.41-.041) .11 .013 -1.65   
Intensive 
Outpatient 
4   .17(.042-.29) .17 .004 2.62**   
Methadone-
assisted 
withdrawal 
1   .76(.31-1.21) .23 .052 3.33***   
Methadone 
maintenance 
1 1.26(.89-1.62) .19 .034 6.76****   
Residential 8   .21(.096-.33) .059 .004 3.59****   
Total between-Q      56.17*** 6 
        
Treatment  
Setting 
       
Addiction rehab 11   .65(.33-.96) .16 .026 4.051****   
Comprehensive 10   .21(.079-.34) .067 .067 3.14***   
Hospital 1   .046(.002-.089) .022 .022 2.061*   
Outpatient 1   .78(.44-1.13) .18 .18 4.43****   
Primary care 1   .094(-.025-.21) .061 .061 1.54   
Total between-Q      34.61**** 4 
Notes: *p<.05. **p<.01. ***p<.001. ****p<.0001.  
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Table 4 
Pearson Correlations between Treatment Effects and Sample Characteristics 
Sample variable  K r p-value 
Mean gestational age 11 -.337 .311 
Treatment length 10 .482 .158 
Attrition rates 17 -.103 .795 
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Table 5 
Individual Study Intervention Groups, Outcome Measures, Effect Sizes, and Weights 
Study Intervention 
Group 
Outcome measure(s) SDM Relative 
Weight 
Elk et al. (1995) 
 
 
 
 
BC w/ IO 
 
 
 
Cocaine free urine samples, cocaine 
metabolite levels 
 
 
0.953 
 
 
 
0.62 
 
 
 
Elk et al. (1998) 
 
 
 
 
 
BC w/ IO 
 
 
 
 
 
Compliance with prenatal visits, 
adverse perinatal outcomes (preterm 
labor & delivery) 
 
 
 
1.521 
 
 
 
 
 
0.35 
 
 
 
 
 
Albrecht, 
Lindsay, & 
Terplan (2011) 
IO 
 
 
Time spent in tx 
 
 
0.132 
 
 
7.83 
 
 
Albrecht, 
Lindsay, & 
Terplan (2011) 
R 
 
 
Time spent in tx 
 
 
0.032 
 
 
7.53 
 
 
Albrecht, 
Lindsay, & 
Terplan (2011) 
 
Detoxification 
 
 
 
Time spent in tx 
 
 
 
0.189 
 
 
 
5.42 
 
 
 
Ingersoll, 
Knisely, 
Dawson, & 
Schnoll (2004)  
BC w/ R+MM 
 
 
 
Time spent in tx 
 
 
 
0.845 
 
 
 
1.07 
 
 
 
Jones, O'Grady, 
Malfi, & Tuten 
(2008) 
MM 
 
 
Time spent in tx, number of prenatal 
visits  
 
1.256 
 
 
3.52 
 
 
TREATMENT	  EFFICACY	  FOR	  ANTENATAL	  SUBSTANCE	  USE	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   37	  
Jones, O'Grady, 
Malfi, & Tuten 
(2008) 
 
7-day 
Methadone-
assisted 
withdrawal  
Time in treatment, head 
circumference  
 
 
0.762 
 
 
 
2.73 
 
 
 
Jones, O’Grady, 
& Tuten (2011) 
 
 
 
 
BC w/IO+MM 
 
 
 
 
 
 
Time in tx, self-reported heroin use, 
self-reported cocaine-use, 
employment rates, time spent in 
hospital  
 
 
 
0.366 
 
 
 
 
 
 
2.86 
 
 
 
 
 
 
Burgdorf, 
Dowell, Chen, 
Roberts, & 
Herrell (2004) 
R 
 
 
 
Infant death, preterm delivery rates, 
birth weight 
 
  
0.046 
 
 
 
7.94 
 
 
 
McMurtrie et al. 
(1999)  
 
 
 
R 
 
 
 
 
Urine toxicity report, mean birth 
weight, intrauterine growth 
retardation  
 
 
0.014 
 
 
 
 
1.24 
 
 
 
 
Metz et al. 
(2011)  
 
 
 
BC w/IO+MM 
 
 
 
 
Need for NAS tx, time spent in 
hospital after birth, neonate need for 
morphine tx  
 
 
0.382 
 
 
 
 
3.26 
 
 
 
 
Metz et al. 
(2011) 
 
 
 
 
 
 
 
MM 
 
 
 
 
 
 
 
 
Gestational age at delivery, birth 
weight, neonate need for morphine 
tx, need for neonatal assisted 
ventilation, time spent in hospital 
after birth, birth weight 
 
 
 
 
0.516 
 
 
 
 
 
 
 
 
3.32 
 
 
 
 
 
 
 
 
Ondersma, 
Winhusen, & 
Lewis (2010) 
IO w/ external 
pressure 
 
Time spent in tx, urine toxicity 
reports, self-reported drug use 
  
0.421 
 
 
4.49 
 
 
Ondersma et al. 
(2009) 
 
 
IO w/ 
Motivational 
enhancement 
therapy 
Time spent in tx, self-reported drug 
use, URICA-derived readiness to 
change scores 
 
0.104 
 
 
 
4.61 
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Porowskki, 
Burgdorf, & 
Herrell (2004) 
R 
 
 
Self-reported drug use, criminal 
activity, employment rates 
 
0.109 
 
 
7.84 
 
 
Rasmussen et al. 
(2012) 
 
 
First Step 
Program 
(community 
based)  
Self-reported drug use, family 
functioning, mother on welfare, 
health/medical problems  
 
0.783 
 
 
 
3.7 
 
 
 
Camp & 
Finkelstein 
(1997) 
Residential (w/ 
parenting skills 
component) 
Self-esteem, parenting skills  
 
 
1.054 
 
 
2.41 
 
 
Silverman et al. 
(2001) 
BC community 
tx+ (IO + MM)  
Time spent in tx, urine toxicity report 
  
0.574 
 
1.64 
 
Svikis, Lee, 
Haug, & Stitzer 
(1997) 
IO w/MM 
 
 
Time spent in tx 
 
 
0.396 
 
 
3.88 
 
 
Jones et al. 
(2001) 
 
BC +  R/IO/MM 
 
 
Time spent in tx, opiate positive urine 
samples, cocaine positive urine 
samples 
0.442 
 
 
2.7 
 
 
Daley et al. 
(2000) 
R 
 
Criminal activity 
 
0.368 
 
4.62 
 
Chang, Carroll, 
Behr, & Kosten  
(1992) 
IO 
 
 
Number of prenatal visits, gestational 
age at delivery, urine toxicity report 
 
0.858 
 
 
0.54 
 
 
Goler, 
Armstrong, 
Taillac, & Osejo 
(2008) 
 
Early Start 
Community-
based program 
 
 
Birth weight, preterm delivery rates, 
placental abruption, preterm labor, 
fetal demise, need for neonatal 
assisted ventilation, admission to ICU 
 
0.094 
 
 
 
 
7.1 
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Connors, Grant, 
Crone, & 
Whiteside-
Mansell (2006) 
 
 
 
R 
 
 
 
 
 
 
Relapse rates, cigarette use, arrest 
rates, employment rates, depressive 
symptoms (BDI-II scores), PTSD 
checklist scores, parenting skills 
(Adult-Adolescent Parenting 
Inventory-2 scores)  
 
.445 
 
 
 
 
 
 
6.48 
 
 
 
 
 
 
Comfort & 
Kaltenbach 
(1999) 
 
 
R 
 
 
 
 
Abstinence rates, birth weight, 
gestational age at delivery, time spent 
in hospital after birth, head 
circumference, self-reported drug use 
 
0.431 
 
 
 
 
2.28 
 
 
 
 
Notes: R=residential treatment; IO=intensive outpatient treatment; MM=methadone maintenance 
treatment, BC=behavioral contingency treatment.  
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Appendix A: Codebook 
 
 
 
Case Number:  
 
Publication Type:  
1) Journal Article 
2) Technical Report  
3) Book or Book Chapter 
4) Dissertation 
5) Abstract 
6) Unpublished Paper 
7) Other 
8) Missing 
 
Publication Date: 
1) 1960s 
2) 1970s 
3) 1980s 
4) 1990s 
5) 2000s 
6) 2010s 
7) Missing  
 
Funding Source:  
1) Federal 
2) Other 
3) Missing  
 
Intervention Type:  
1) Methadone Maintenance 
2) Inpatient Hospitalization 
3) Residential (Full) 
4) Residential (Partial) 
5) Intensive Outpatient  
6) Outpatient  
7) Detoxification  
8) Therapeutic Community  
9) Combination  
10) Other      
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a. Specify:   
b.  
Comparison Group 1 Type: 
1) Methadone Maintenance 
2) Inpatient Hospitalization 
3) Residential (Full) 
4) Residential (Partial) 
5) Intensive Outpatient  
6) Outpatient  
7) Detoxification  
8) Therapeutic Community  
9) Other  
a. Specify:  
10) Wait List Control  
11) No Treatment  
12) Minimal Contact  
 
Comparison Group 2 Type: 
1) Methadone Maintenance 
2) Inpatient Hospitalization 
3) Residential (Full) 
4) Residential (Partial) 
5) Intensive Outpatient  
6) Outpatient  
7) Detoxification  
8) Therapeutic Community  
9) Other  
a. Specify:  
10) Wait List Control  
11) No Treatment  
12) Minimal Contact  
Comparison Group 3 Type: 
1) Methadone Maintenance 
2) Inpatient Hospitalization 
3) Residential (Full) 
4) Residential (Partial) 
5) Intensive Outpatient  
6) Outpatient  
7) Detoxification  
8) Therapeutic Community  
9) Other  
a. Specify:  
10) Wait List Control  
11) No Treatment  
12) Minimal Contact  
Comparison Group 4 Type: 
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1) Methadone Maintenance 
2) Inpatient Hospitalization 
3) Residential (Full) 
4) Residential (Partial) 
5) Intensive Outpatient  
6) Outpatient  
7) Detoxification  
8) Therapeutic Community  
9) Other  
a. Specify:  
10) Wait List Control  
11) No Treatment  
12) Minimal Contact  
 
Treatment Setting: 
1) Comprehensive Care 
2) Outpatient Mental Health 
3) Addiction Rehab 
4) Primary Care Facility  
5) Hospital 
6) Other 
a. Specify 
 
Substance Type: 
1) Polydrug 
2) Illicit 
3) Alcohol  
4) Tobacco 
5) Cocaine  
6) Heroin 
7) Opiates and cocaine 
8) Other 
a. Specify  
 
Is study specifically examining pregnant women?  
1) Yes 
2) No 
 
Type of maternal population being examined:  
1) Antenatal 
2) Antenatal and Postnatal 
3) Postnatal  
 
Target time of treatment admittance:  
1) First trimester 
2) Second trimester 
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3) Third trimester  
 
Mean gestational age at start of treatment?  (in weeks)  
 
Type of research design: 
1) Single group, repeated measures 
2) Active comparison group(s) (routine treatment, treatment as usual, alternative 
treatment, placebo treatment)  
3) Passive comparison group(s)  (delayed treatment/wait list control, no 
treatment, minimal contact)  
4) Combination of active and passive comparison groups  
 
Assignment procedures to treatment groups (* N/A if it’s a single group, repeated measures 
design): 
1) Random, quasi-random 
2) Nonrandom, matching  
3) Nonrandom, no matching  
 
Number of subjects in total sample (of pregnant women):  
 
Mean age of subjects: 
 
Sample size of Intervention condition:  
 
Sample size of Comparison 1 group:  
 
Sample size of Comparison 2 group: 
 
Sample size of Comparison 3 group: 
 
Sample size of Comparison 4 group: 
 
White sample size:  
 
Black sample size:  
 
Hispanic/Latino sample size: 
 
Asian sample size:  
 
American Indian/Alaska Native sample size:  
 
Native Hawaiian/Pacific Islander sample size:  
 
Other racial/ethnic group sample size:  
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Type of Comorbid mood disorder measured:   
1) Mood disorder (in general) 
2) Major Depressive Disorder 
3) Depression  
 
Sample size with mood disorder:  
 
Sample size with anxiety disorder:  
 
Sample size that’s HIV+ :  
 
Sample size that experienced/experiences domestic violence:  
 
Length of Intervention Condition in weeks:  
 
Average time participants spent in treatment (in weeks):  
 
Rate (%) of attrition/treatment dropout in total sample:  
 
Proportion (%) of treatment completers:  
 
Frequency (%) of service utilization:  
 
Rate (%) of sample that engaged in detox/treatment readmission during the course study:  
 
Comparison A:  
Type of comparisonA used to measure treatment efficacy/effectiveness:  
1) Single group, repeated measures 
2) Intervention group with Comparison 1 group 
3) Intervention group with Comparison 2 group 
4) Intervention group with Comparison 3 group 
5) Intervention group with Comparison 4 group 
 
 
Type of Outcome Measure used in Comparison A:  
1) Drug use outcomes  
a. 1.10 Self-reported drug use 
b. 1.20 Urine toxicology reports 
c. 1.30 Relapse rates 
d. 1.40 Abstinence rates 
e. 1.50 Cocaine Metabolite  
f. 1.60 Addiction Severity Index  
2) Maternal outcomes 
a. 2.10 Number of prenatal visits 
b. 2.20 Compliance with prenatal visits 
c. 2.30 Self-esteem 
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d. 2.40 Parenting skills 
e. 2.50 Family functioning  
f. 2.60 Child in foster care  
g. 2.70 Health/Medical problems 
h. 2.80 Criminal activity  
i. 2.90 Employment rates  
3) Birth Outcomes 
a. 3.05 Gestational age at delivery 
b. 3.10 Preterm delivery rates 
c. 3.15 Placenta abruption  
d. 3.20 Fetal demise 
e. 3.25 Intrauterine growth retardation 
f. 3.30 Birth weight 
g. 3.35 APGAR scores 
h. 3.40 Admission to ICU 
i. 3.45 Length at birth  
j. 3.50 Infant death  
k. 3.55 Head circumference  
l. 3.60 Re-hospitalization within 30 days of delivery 
m. 3.65 Need for neonatal assisted ventilation  
n. 3.70 Cesarean birth 
o. 3.75 Sudden Infant Death Syndrome 
 
Time of Assessment (most interested in time closest to first post-treatment point)  
1) Pre-treatment 
2) Baseline 
3) During active treatment  
4) Treatment completion 
5) Post-treatment 
 
Second time used to evaluate mean changes in Singe group, repeated measures design:  
1) Pre-treatment 
2) Baseline 
3) During active treatment 
4) Treatment completion 
5) Post-treatment  
 
Type of statistic reported for ComparisonA: 
1) Mean (or mean difference)  
2) Standard deviation 
3) Percentage/Proportion  
4) T statistic  
5) Z statistic  
6) F statistic  
7) X2 statistic  
8) Odds ratio 
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9) One-sided p value 
 
Reported Value of this statistic:  
 
 
Reported P value of significance:  
1) <.05 
2) <.01 
3) <.001 
 
Reported value of effect size (Cohen’s d) :  
 	  	  
 	  
